Nucleoside transporters: Molecular biology and implications for therapeutic development

Molecular Medicine Today

Volumn 5, Issue 5, 1999, Pages 216-224

  Baldwin, Stephen A ^a   Mackey, John R ^b   Cass, Carol E ^b   Young, James D ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; CLADRIBINE; CYTARABINE; DIAMIDINE DERIVATIVE; DIPYRIDAMOLE; DRAFLAZINE; FLUDARABINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; HYPOXANTHINE; LOMETREXOL; MELARSOPROL; NUCLEOSIDE ANALOG; PENTAMIDINE; VIDARABINE;

AFRICAN TRYPANOSOMIASIS; BLOOD DISEASE; BLOOD VESSEL TONE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELL MEMBRANE TRANSPORT; DRUG TRANSPORT; DRUG UPTAKE; GASTROINTESTINAL TOXICITY; HEART MUSCLE CELL; HUMAN; MOLECULAR BIOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEIC ACID SYNTHESIS; NUCLEOSIDE TRANSPORT; PARASITOSIS; REVIEW; SOLID TUMOR;

ANIMALS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES; PROTOZOAN INFECTIONS;

EID: 0033136943     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01459-8     Document Type: Review

References (48)

1. 1 Shryock, J.C. and Belardinelli, L. (1997) Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology, Am. J. Cordiol. 79, 2-10
2. 2 Murray, A.W. (1971) The biological significance of purine salvage, Annu. Rev. Biochem. 40, 811-826
3. 3 Berens, R.L., Krug, E.C. and Marr, J.J. (1995) Purine and pyrimidine metabolism, in Biochemistry of Parasitic Organisms and Its Molecular Foundations (Marr, J.J. and Müller, M., eds), pp. 89-117, Academic Press
4. 4 Senft, A.W., Miech, R.P., Brown, P.R. and Senft, D.G. (1972) Purine metabolism in Schistosoma mansoni, Int. J. Parasitol. 2, 249-260
5. 5 Griffith, D.A. and Jarvis, S.M. (1996) Nucleoside and nucleobase transport systems of mammalian cells, Biochim. Biophys. Acta 1286, 153-181
6. 6 Cass, C.E. et al. Nucleoside transporters of mammalian cells, in Membrane Transporters as Targets (Amidon, G. and Sadee, W., eds), Plenum Publishing Corporation (in press)
7. 7 Mackey, J.R., Baldwin, S.A., Young, J.D. and Cass, C.E. (1998) Nucleoside transport and its significance for anticancer drug resistance, Drug Resistance Updates 1, 310-324
8. 8 Crawford, C.R., Patel, D.H., Naeve, C. and Belt, J.A. (1998) Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line, J. Biol. Chem. 273, 5288-5293
9. 9 Osses, N., Pearson, J.D., Yudilevich, D.L. and Jarvis, S.M. (1996) Hypoxanthine enters human vascular endothelial cells (ECV 304) via the nitrobenzylthioinosine-insensitive equilibrative nucleoside transporter, Biochem. J. 317, 843-848
10. +-dependent nucleoside transporters, Pharm. Res. 14, 1524-1532
11. 11 Griffiths, M. et al. (1997) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs, Nat. Med. 3, 89-93
12. 12 Griffiths, M. et al. (1997) Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta, Biochem. J. 328, 739-743
13. 13 Huang, Q-Q. et al. (1994) Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein, J. Biol. Chem. 269, 17757-17760
14. +-nucleoside co-transporter, J. Biol. Chem. 270, 13596-13599
15. 15 Yao, S.Y.M. et al. (1996) Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed ta Xenopus laevis oocytes, Mol. Pharmacol. 50, 1529-1535
16. +-nucleoside cotransporter (hCNT1), Am. J. Physiol. 41, C707-C714
17. +-dependent purine nucleoside transporter from human kidney: cloning and functional characterization, Am. J. Physiol. 42, F1058-F1065
18. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine, Mol. Membrane Biol. 15, 203-211
19. 19 Tattersall, M.H.N., Slowiaczek, P. and De Fazio, A. (1983) Regional variation in human extracellular purine levels, J. Lab. Clin. Med. 102, 411-420
20. 20 Vasudevan, G. et al. (1998) Cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant, Proc. Natl. Acad. Sci. U. S. A. 95, 9873-9878
21. 21 Fang, X. et al. (1996) Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1(rat)) by transient expression in cultured mammalian cells, Biochem. J. 317, 457-465
22. 22 Schaner, M.E. et al. (1997) Transient expression of a purine-selective nucleoside transporter (SPNTint) in a human cell line (HeLa), Pharm. Res. 14, 1316-1321
23. +-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells, Biochem. J. 330, 997-1001
24. 24 Anderson, C.M. et al. (1996) Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain, Mol. Brain Res. 42, 358-361
25. 25 Hamilton, S.R. et al. (1997) Anti-peptide antibodies as probes of the structure and subcellular distribution of the sodium-dependent nucleoside transporter, rCNT1, J. Physiol. 499P, P50-P51
26. 26 Craig, J.E., Zhang, Y. and Gallagher, M.P. (1994) Cloning of the nupC gene of Escherichia coli encoding a nucleoside transport system, and identification of an adjacent insertion element, IS 186, Mol. Microbiol. 11, 1159-1168
27. +-dependent nucleoside transporters, J. Biol. Chem. 272, 28845-28848
28. 28 Plunkett, W. and Gandhi, V. (1997) Nucleoside analogs: cellular pharmacology, mechanisms of action, and strategies for combination therapy, in Nucleoside Analogs in Cancer Therapy (Cheson, B.D., Keating, M.J. and Plunkett, W., eds), pp. 1-35, Marcel Dekker
29. 29 Wiley, J.S., Jones, S.P., Sawyer, W.H. and Paterson, A.R.P. (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukaemia, J. Clin. Invest. 69, 479-489
30. 30 Wiley, J.S. et al. (1987) Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia, Aust. New Zealand J. Med. 17, 379-386
31. 31 Mackey, J.R. et al. (1998) Functional nucleoside transporters are required for gemcitabine influx and cytotoxicity in cancer cell lines, Cancer Res. 58, 4349-4357
32. 32 Dagnino, L. and Paterson, A.R.P. (1990) Sodium-dependent and equilibrative nucleoside transport systems in L1210 mouse leukemia cells: effect of inhibitors of equilibrative systems on the content and retention of nucleosides, Cancer Res. 50, 6549-6553
33. 33 Turner, R.N., Aherne, G.W. and Curtin, N.J. (1997) Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage, Br. J. Cancer 76, 1300-1307
34. 34 Marshman, E. et al. (1998) Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro, Clin. Cancer Res. 4, 2895-2902
35. 35 Faaland, C.A. et al. (1998) Molecular characterization of two novel transporters from human and mouse kidney and from LLC-PK1 cells reveals a novel conserved family that is homologous to bacterial and Aspergillus nucleobase transporters, Biochim. Biophys. Acta 1442, 353-360
36. 36 Willson, J.K. et al. (1988) Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage, Cancer. Res. 48, 5585-5590
37. 37 Mubagwa, K., Mullane, K. and Flameng, W. (1996) Role of adenosine in the heart and circulation, Cardiovasc. Res. 32, 797-813
38. 38 Decking, U.K., Schlieper, G., Kroll, K. and Schrader, J. (1997) Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release, Circ. Res. 81, 154-164
39. 39 Lasley, R.D. and Mentzer, R.M. (1996) Myocardial protection: the adenosine story, Drug Dev. Res. 39, 314-318
40. 40 Martin, B.J., Lasley, R.D. and Mentzer, R.M. (1997) Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine, Am. J. Physiol. 41, H1857-H1865
41. 41 Sundaram, M. et al. (1998) Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs, J. Biol. Chem. 273, 21519-21525
42. 42 Van Belle, H., Goossens, F. and Wynants, J. (1987) Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia, Am. J. Physiol. 252, H886-H893
43. 43 Mullane, K. and Bullough, D. (1995) Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine, J. Mol. Cell Cardiol. 27, 1041-1054
44. 44 Carter, N.S. and Fairlamb, A.H. (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter, Nature 361, 173-176
45. 45 Barrett, M. and Fairlamb, A.H. (1999) The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes, Parasitol. Today 15, 136-140
46. 46 De Koning, H.P., Watson, C.J. and Jarvis, S.M. (1998) Characterization of a nucleoside/proton symporter in procyclic Trypanosoma brucei brucei, J. Biol. Chem. 273, 9486-9494
47. 47 Tye, C-K. et al. (1998) An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes, Bioorgan. Med. Chem. Lett. 8, 811-816
48. 48 el Kouni, M.H. et al. (1989) Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5'-monophosphate for the treatment of schistosomiasis, Antimicrob. Agents Chemother. 33, 824-827